Table 3.

Ongoing clinical trials of radiotherapy and immune checkpoint inhibitor combination in locally advanced stage non-small cell lung cancer in the adjuvant/consolidation setting

Ref.	Phase	Design	No.of patients	Tumor stage	RT	ICI agent	Sequence	Status
BTCRC-LUN16-081, NCT03285321[50]	2 randomized	Concomitant definitive CRT followed by consolidative ICI (3 CT regimens: CDDP-VP16 vs Carbo-Taxol vs Cisplatin- Pemetrexed)	108	Unresectable IIIA-IIIB	59.4-66.6 Gy	Nivolumab +/-Ipilimumab	Consolidation afterdefinitive treatment	Recruiting
NCT03589547[81]	2	CRT followed by consolidative ICI and SABR	25	III	60 Gy followed by SBRT 20 Gy/2-3 fx	Durvalumab	Consolidation after definitive treatment (ICI prior to SABR)	Recruiting
PACIFIC 6, NCT03693300[82]	2	ICI after sequential CRT	150	Unresectable III	Conventional RT; 60 Gy/30 fx	Durvalumab	Consolidation after definitive treatment (within 28 d after RT)	Active, not recruiting
MK-3475, NCT03379441[83]	2	Maintenance ICI after definitive CRT	126	Unresectable IIIA-IIIB	Conventional RT	Pembrolizumab	Consolidation afterdefinitive treatment	Not recrutiing
DUART,NCT 04249362[84]	2 single arm	RT followed by ICI	150	Unresectable III	Conventional RT 60 Gy Hypofractionated RT 40-54 Gy	Durvalumab	Consolidation after RT (no CT)	Recruiting
PACIFIC 5, NCT03706690[47]	3 randomized, doube-blinded	Consolidative ICI vs placebo after definitive CRT radical (concomitant or sequential)	360	Unresectable III	Conventional RT	Durvalumab	Consolidation after definitive treatment	Recruiting

RT: Radiotherapy; CRT: Chemoradiotherapy; CT: Chemotherapy; ICI: Immune checkpoint inhibitor; Gy: Gray.